Eleven Biotherapeutics reports $33.5 million net loss in 2015

Eleven Biotherapeutics reported a net loss applicable to common stockholders of $33.5 million, or $1.76 per share, in 2015 compared with $34.7 million, or $2.37 per share, in 2014, according to a company press release.

Research and development expenses were reported at $26.3 million in 2015 compared with $26.7 million in 2014. Research and development expenses increased from $5.3 million in the fourth quarter of 2014 to $8.1 million for the same quarter in 2015, partly attributable to expenses related to development of EBI-031, the company’s preclinical product candidate for treatment of diabetic macular edema and uveitis, offset by decreased expenses related to development of EBI-005 (isunakinra), which the company is no longer pursuing as a treatment for allergic conjunctivitis, according to the release.

General and administrative expenses were reported at $9.9 million in 2015 vs. $8.5 million in 2014.

Revenue was reported at $1 million in 2015 compared with $2.2 million in 2014.